{"organizations": [], "uuid": "924efacfc63d1b7cce52a898e0b09a8d0ce8ec7f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530554?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Protagonist closes $40mm Series C", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Protagonist closes $40mm Series C", "spam_score": 0.0, "site_type": "news", "published": "2015-07-17T02:30:00.000+03:00", "replies_count": 0, "uuid": "924efacfc63d1b7cce52a898e0b09a8d0ce8ec7f"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530554?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Protagonist closes $40mm Series C", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Protagonist closes $40mm Series C Deal Date: Jul-01-2015 / Deal # 201530554 Executive Summary \nProtagonist Therapeutics Inc. (peptide drug candidates for gastrointestinal diseases) raised $40mm through its Series C financing from new investors Canaan Partners (lead; adds a board member), Adage Capital Management, RA Capital Management, and Foresite Capital, and returning shareholders Johnson & Johnson Development Corp., Lilly Ventures, Pharmstandard , and Starfish Ventures. Funds will help move the company's lead compound PTG100 into the clinic later this year for inflammatory bowel diseases, and also advance other pipeline programs.", "external_links": [], "published": "2015-07-17T02:30:00.000+03:00", "crawled": "2015-07-17T14:30:05.000+03:00", "highlightTitle": ""}